Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 3, 2026, 6:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Healthy
Interventions
Sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Solid Tumor
Interventions
NP-101
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Neoplasm, Neuroendocrine Carcinoma, Mixed Neuroendocrine-Non Neuroendocrine Neoplasm
Interventions
NP-101 (TQ Formula), Nivolumab (3mg/kg), Ipilimumab (1mg/kg)
Drug
Lead sponsor
Amr Mohamed MD
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Conditions
Migraine Disorders
Interventions
Sumatriptan succinate, NP101 Study Patch
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Hallandale, Florida
Conditions
Migraine Disorders
Interventions
NP101 Sumatriptan Iontophoretic Transdermal Patch
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Compare Bioequivalence Patches Previously Used in the NP101-007 Study
Interventions
NP101, sumatriptan succinate
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Migraine Disorders
Interventions
NP101
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Irvine, California + 28 more
Conditions
Migraine Disorders
Interventions
NP101 - Sumatriptan iontophoretic transdermal patch, Placebo
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Conditions
Hepatocellular Carcinoma
Interventions
NP-101 (3 g), NP-101 (4.8 g), NP-101 (6 g)
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
COVID-19
Interventions
NP-101, Placebo
Drug · Other
Lead sponsor
Novatek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Miami, Florida • Berwyn, Illinois • Houston, Texas + 1 more